Clinical Supply Planning For Studies With Unconventional Timelines

As a result of the industry's ongoing desire to save time, reduce costs, and get therapeutics to market as quickly and safely as possible, more drug sponsors are considering the advantages of conducting studies that deviate from standard timelines, including combined phases and adaptive designs. ​In this Q&A, Rajeev Daniel, Regional Manager, Clinical Supply Management at Catalent, discusses how these unconventional trials impact the supply chain, the role a CDMO can play in facilitating these trials, and the possible risks of such studies.